Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 8 | 2023 | 77 | 3.930 |
Why?
|
| Neoadjuvant Therapy | 4 | 2020 | 321 | 1.370 |
Why?
|
| Ileostomy | 2 | 2018 | 26 | 1.160 |
Why?
|
| Crohn Disease | 3 | 2019 | 283 | 1.050 |
Why?
|
| Robotic Surgical Procedures | 2 | 2021 | 194 | 1.030 |
Why?
|
| Laparoscopy | 3 | 2023 | 501 | 1.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 1067 | 0.920 |
Why?
|
| Patient Readmission | 2 | 2018 | 365 | 0.910 |
Why?
|
| Pelvis | 2 | 2023 | 68 | 0.800 |
Why?
|
| Narcotics | 1 | 2022 | 63 | 0.780 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2021 | 354 | 0.770 |
Why?
|
| Deoxycytidine | 1 | 2021 | 77 | 0.720 |
Why?
|
| Colectomy | 2 | 2022 | 75 | 0.720 |
Why?
|
| Robotics | 1 | 2021 | 106 | 0.690 |
Why?
|
| Simulation Training | 1 | 2021 | 139 | 0.650 |
Why?
|
| General Surgery | 2 | 2019 | 203 | 0.640 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 258 | 0.630 |
Why?
|
| Colonic Neoplasms | 2 | 2021 | 247 | 0.630 |
Why?
|
| Colorectal Surgery | 1 | 2018 | 9 | 0.620 |
Why?
|
| Biological Factors | 1 | 2018 | 28 | 0.620 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 27 | 0.610 |
Why?
|
| Colorectal Neoplasms | 2 | 2021 | 560 | 0.600 |
Why?
|
| Elective Surgical Procedures | 1 | 2018 | 161 | 0.560 |
Why?
|
| Ileum | 2 | 2019 | 132 | 0.560 |
Why?
|
| Preoperative Care | 2 | 2018 | 350 | 0.550 |
Why?
|
| Peritoneal Diseases | 1 | 2016 | 9 | 0.550 |
Why?
|
| Medical Oncology | 1 | 2018 | 213 | 0.550 |
Why?
|
| Students, Medical | 1 | 2021 | 358 | 0.550 |
Why?
|
| Hirschsprung Disease | 1 | 2016 | 36 | 0.540 |
Why?
|
| Postoperative Complications | 4 | 2023 | 3005 | 0.510 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 280 | 0.490 |
Why?
|
| Abscess | 1 | 2016 | 138 | 0.490 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 154 | 0.490 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 499 | 0.460 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 441 | 0.440 |
Why?
|
| Pelvic Neoplasms | 1 | 2013 | 21 | 0.440 |
Why?
|
| Myxoma | 1 | 2013 | 28 | 0.440 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 640 | 0.400 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 1215 | 0.400 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1253 | 0.380 |
Why?
|
| Internship and Residency | 2 | 2019 | 1158 | 0.360 |
Why?
|
| Telemedicine | 1 | 2017 | 421 | 0.360 |
Why?
|
| Dissection | 2 | 2023 | 52 | 0.360 |
Why?
|
| Circulating Tumor DNA | 2 | 2021 | 32 | 0.350 |
Why?
|
| Postoperative Period | 2 | 2022 | 330 | 0.320 |
Why?
|
| Fluorouracil | 2 | 2021 | 129 | 0.320 |
Why?
|
| Humans | 25 | 2023 | 122998 | 0.310 |
Why?
|
| Retrospective Studies | 6 | 2023 | 15931 | 0.290 |
Why?
|
| Florida | 2 | 2017 | 72 | 0.290 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 860 | 0.280 |
Why?
|
| Treatment Outcome | 6 | 2021 | 12087 | 0.270 |
Why?
|
| Aged | 8 | 2018 | 19035 | 0.270 |
Why?
|
| Male | 13 | 2023 | 59901 | 0.260 |
Why?
|
| Middle Aged | 8 | 2018 | 25931 | 0.250 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1240 | 0.250 |
Why?
|
| Female | 14 | 2021 | 65310 | 0.220 |
Why?
|
| Prognosis | 3 | 2021 | 4490 | 0.200 |
Why?
|
| Morphine | 1 | 2022 | 87 | 0.200 |
Why?
|
| Adult | 6 | 2018 | 28980 | 0.190 |
Why?
|
| Capecitabine | 1 | 2021 | 17 | 0.190 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2018 | 84 | 0.180 |
Why?
|
| Career Choice | 1 | 2021 | 143 | 0.180 |
Why?
|
| Rectum | 1 | 2020 | 98 | 0.170 |
Why?
|
| Standard of Care | 1 | 2020 | 129 | 0.170 |
Why?
|
| Risk Assessment | 2 | 2018 | 3325 | 0.160 |
Why?
|
| Pain | 1 | 2022 | 470 | 0.160 |
Why?
|
| Pain, Postoperative | 1 | 2021 | 254 | 0.160 |
Why?
|
| Computer Simulation | 1 | 2021 | 636 | 0.160 |
Why?
|
| Community Networks | 1 | 2018 | 33 | 0.150 |
Why?
|
| United States | 4 | 2022 | 10595 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2018 | 82 | 0.150 |
Why?
|
| Operative Time | 1 | 2018 | 160 | 0.150 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 146 | 0.150 |
Why?
|
| Hernia | 1 | 2017 | 19 | 0.150 |
Why?
|
| Cadaver | 1 | 2017 | 131 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2019 | 403 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 1230 | 0.140 |
Why?
|
| Perineum | 1 | 2017 | 50 | 0.140 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 217 | 0.140 |
Why?
|
| Surgical Mesh | 1 | 2017 | 62 | 0.140 |
Why?
|
| Leadership | 1 | 2019 | 227 | 0.140 |
Why?
|
| Dehydration | 1 | 2017 | 37 | 0.140 |
Why?
|
| Schools, Medical | 1 | 2017 | 112 | 0.140 |
Why?
|
| Herniorrhaphy | 1 | 2017 | 80 | 0.140 |
Why?
|
| Mesentery | 1 | 2016 | 28 | 0.140 |
Why?
|
| Age of Onset | 1 | 2018 | 581 | 0.140 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 80 | 0.130 |
Why?
|
| Telephone | 1 | 2017 | 109 | 0.130 |
Why?
|
| Fibrosis | 1 | 2018 | 429 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 270 | 0.130 |
Why?
|
| Faculty, Medical | 1 | 2019 | 263 | 0.130 |
Why?
|
| Young Adult | 3 | 2018 | 8840 | 0.130 |
Why?
|
| Intestinal Obstruction | 1 | 2017 | 97 | 0.130 |
Why?
|
| Hospital Costs | 1 | 2017 | 177 | 0.130 |
Why?
|
| Surgical Flaps | 1 | 2017 | 206 | 0.120 |
Why?
|
| Counseling | 1 | 2017 | 219 | 0.120 |
Why?
|
| Carcinoma | 1 | 2017 | 278 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2021 | 978 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2018 | 1470 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2018 | 678 | 0.120 |
Why?
|
| Intestines | 1 | 2018 | 571 | 0.110 |
Why?
|
| Colonic Diseases | 1 | 2014 | 38 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 313 | 0.110 |
Why?
|
| Intussusception | 1 | 2014 | 46 | 0.110 |
Why?
|
| Sacrococcygeal Region | 1 | 2013 | 32 | 0.110 |
Why?
|
| Logistic Models | 1 | 2018 | 1796 | 0.110 |
Why?
|
| Survival Rate | 1 | 2018 | 1993 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2017 | 1386 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 476 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1430 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 2105 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2018 | 1542 | 0.100 |
Why?
|
| Age Factors | 1 | 2018 | 2801 | 0.100 |
Why?
|
| Length of Stay | 1 | 2017 | 1283 | 0.090 |
Why?
|
| Adolescent | 2 | 2018 | 19030 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2018 | 4705 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 3657 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6359 | 0.070 |
Why?
|
| Risk Factors | 1 | 2018 | 9974 | 0.060 |
Why?
|
| Catastrophization | 1 | 2021 | 14 | 0.050 |
Why?
|
| Inflammation | 2 | 2019 | 1400 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2020 | 12 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2020 | 28 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2021 | 349 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 121 | 0.040 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 2 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Interleukin-23 | 1 | 2019 | 12 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2019 | 53 | 0.040 |
Why?
|
| Sexism | 1 | 2019 | 37 | 0.040 |
Why?
|
| Tyrosine | 1 | 2019 | 152 | 0.040 |
Why?
|
| Gender Identity | 1 | 2019 | 69 | 0.040 |
Why?
|
| Elasticity | 1 | 2018 | 92 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2018 | 110 | 0.040 |
Why?
|
| Colon | 1 | 2020 | 353 | 0.040 |
Why?
|
| Autografts | 1 | 2017 | 26 | 0.040 |
Why?
|
| Species Specificity | 1 | 2018 | 549 | 0.040 |
Why?
|
| Cattle | 1 | 2018 | 559 | 0.040 |
Why?
|
| Ascites | 1 | 2017 | 87 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2019 | 374 | 0.030 |
Why?
|
| Pain Management | 1 | 2017 | 171 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1254 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 1610 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 292 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 1155 | 0.030 |
Why?
|
| Malnutrition | 1 | 2017 | 196 | 0.030 |
Why?
|
| Gene Expression | 1 | 2018 | 1569 | 0.030 |
Why?
|
| Palliative Care | 1 | 2017 | 428 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 2027 | 0.030 |
Why?
|
| Uterus | 1 | 2017 | 594 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 2940 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 6023 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 4342 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 5031 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 4263 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2041 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3510 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 33693 | 0.010 |
Why?
|